BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 7.695 USD 0.72%
Market Cap: 1.6B USD
Have any thoughts about
BioCryst Pharmaceuticals Inc?
Write Note

Intrinsic Value

The intrinsic value of one BCRX stock under the Base Case scenario is 11.43 USD. Compared to the current market price of 7.695 USD, BioCryst Pharmaceuticals Inc is Undervalued by 33%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BCRX Intrinsic Value
11.43 USD
Undervaluation 33%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
BioCryst Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BCRX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BCRX?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about BioCryst Pharmaceuticals Inc

Provide an overview of the primary business activities
of BioCryst Pharmaceuticals Inc.

What unique competitive advantages
does BioCryst Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does BioCryst Pharmaceuticals Inc face in the near future?

Summarize the latest earnings call
of BioCryst Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for BioCryst Pharmaceuticals Inc.

Provide P/S
for BioCryst Pharmaceuticals Inc.

Provide P/E
for BioCryst Pharmaceuticals Inc.

Provide P/OCF
for BioCryst Pharmaceuticals Inc.

Provide P/FCFE
for BioCryst Pharmaceuticals Inc.

Provide P/B
for BioCryst Pharmaceuticals Inc.

Provide EV/S
for BioCryst Pharmaceuticals Inc.

Provide EV/GP
for BioCryst Pharmaceuticals Inc.

Provide EV/EBITDA
for BioCryst Pharmaceuticals Inc.

Provide EV/EBIT
for BioCryst Pharmaceuticals Inc.

Provide EV/OCF
for BioCryst Pharmaceuticals Inc.

Provide EV/FCFF
for BioCryst Pharmaceuticals Inc.

Provide EV/IC
for BioCryst Pharmaceuticals Inc.

Show me price targets
for BioCryst Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for BioCryst Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for BioCryst Pharmaceuticals Inc?

What are the Net Income projections
for BioCryst Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for BioCryst Pharmaceuticals Inc?

What are the EPS projections
for BioCryst Pharmaceuticals Inc?

How accurate were the past EPS estimates
for BioCryst Pharmaceuticals Inc?

What are the EBIT projections
for BioCryst Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for BioCryst Pharmaceuticals Inc?

Compare the revenue forecasts
for BioCryst Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of BioCryst Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of BioCryst Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of BioCryst Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of BioCryst Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing BioCryst Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of BioCryst Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for BioCryst Pharmaceuticals Inc.

Provide ROE
for BioCryst Pharmaceuticals Inc.

Provide ROA
for BioCryst Pharmaceuticals Inc.

Provide ROIC
for BioCryst Pharmaceuticals Inc.

Provide ROCE
for BioCryst Pharmaceuticals Inc.

Provide Gross Margin
for BioCryst Pharmaceuticals Inc.

Provide Operating Margin
for BioCryst Pharmaceuticals Inc.

Provide Net Margin
for BioCryst Pharmaceuticals Inc.

Provide FCF Margin
for BioCryst Pharmaceuticals Inc.

Show all solvency ratios
for BioCryst Pharmaceuticals Inc.

Provide D/E Ratio
for BioCryst Pharmaceuticals Inc.

Provide D/A Ratio
for BioCryst Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for BioCryst Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for BioCryst Pharmaceuticals Inc.

Provide Quick Ratio
for BioCryst Pharmaceuticals Inc.

Provide Current Ratio
for BioCryst Pharmaceuticals Inc.

Provide Cash Ratio
for BioCryst Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for BioCryst Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for BioCryst Pharmaceuticals Inc?

What is the current Free Cash Flow
of BioCryst Pharmaceuticals Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for BioCryst Pharmaceuticals Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BioCryst Pharmaceuticals Inc

Current Assets 363.5m
Cash & Short-Term Investments 272m
Receivables 68.8m
Other Current Assets 22.7m
Non-Current Assets 109m
Long-Term Investments 64.3m
PP&E 7.7m
Other Non-Current Assets 37m
Current Liabilities 129.1m
Accounts Payable 7.8m
Accrued Liabilities 90.6m
Other Current Liabilities 30.7m
Non-Current Liabilities 819m
Long-Term Debt 810.6m
Other Non-Current Liabilities 8.4m
Efficiency

Earnings Waterfall
BioCryst Pharmaceuticals Inc

Revenue
412.6m USD
Cost of Revenue
-8m USD
Gross Profit
404.6m USD
Operating Expenses
-445.3m USD
Operating Income
-40.7m USD
Other Expenses
-83.1m USD
Net Income
-123.8m USD

Free Cash Flow Analysis
BioCryst Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BCRX Profitability Score
Profitability Due Diligence

BioCryst Pharmaceuticals Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
Positive Gross Profit
ROIC is Increasing
49/100
Profitability
Score

BioCryst Pharmaceuticals Inc's profitability score is 49/100. The higher the profitability score, the more profitable the company is.

BCRX Solvency Score
Solvency Due Diligence

BioCryst Pharmaceuticals Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
33/100
Solvency
Score

BioCryst Pharmaceuticals Inc's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BCRX Price Targets Summary
BioCryst Pharmaceuticals Inc

Wall Street analysts forecast BCRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BCRX is 14.744 USD with a low forecast of 7.07 USD and a high forecast of 31.5 USD.

Lowest
Price Target
7.07 USD
8% Downside
Average
Price Target
14.744 USD
92% Upside
Highest
Price Target
31.5 USD
309% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BCRX?

Click here to dive deeper.

Dividends

BioCryst Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for BCRX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.6B USD

Dividend Yield

0%

Description

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.

Contact

NORTH CAROLINA
Durham
4505 Emperor Blvd Ste 200
+19198591302.0
www.biocryst.com

IPO

1994-03-04

Employees

358

Officers

CEO, President & Executive Director
Mr. Jon P. Stonehouse
Senior VP, CFO & Interim Principal Accounting Officer
Mr. Anthony J. Doyle
Senior VP, Chief Legal Officer & Corporate Secretary
Ms. Alane P. Barnes
Chief Research & Development Officer
Dr. Helen M. Thackray FAAP, M.D.
Senior VP & Chief Commercial Officer
Mr. Charles K. Gayer
Chief Communications Officer
Mr. John D. Bluth
Show More
Chief People Officer
Ms. Stephanie Angelini
Chief Development Officer
Dr. William P. Sheridan MBBS
Chief Discovery Officer
Dr. Yarlagadda S. Babu Ph.D.
Chief Data & Insights Officer
Ms. Jinky Ang Rosselli
Show Less

See Also

Discover More
What is the Intrinsic Value of one BCRX stock?

The intrinsic value of one BCRX stock under the Base Case scenario is 11.43 USD.

Is BCRX stock undervalued or overvalued?

Compared to the current market price of 7.695 USD, BioCryst Pharmaceuticals Inc is Undervalued by 33%.

Back to Top